Question 1

What sectors does ProGen Search cover?

Accepted Answer

ProGen Search covers seven complex life sciences sectors: Radiopharma (radiopharmaceuticals, radioligand therapy, isotope supply), CDMO (contract development and manufacturing organisations), CRO (contract research organisations), ADC (antibody-drug conjugates), Cell & Gene Therapy (viral vector manufacturing, cell processing, ATMPs), Biotech & Pharma (drug development, CMC, regulatory, clinical, commercial), and Life Sciences Software (LIMS, QMS, MES, CTMS, AI/ML platforms).

Question 2

What level of roles does ProGen Search recruit for?

Accepted Answer

ProGen Search exclusively handles retained executive searches at VP to C-suite level. This includes VP Manufacturing, VP Quality, VP CMC, VP Regulatory Affairs, VP MSAT, VP Business Development, Site Heads, Chief Executive Officers, Chief Operating Officers, Chief Scientific Officers, Chief Medical Officers, and Chief Technology Officers. No contingent work or volume hiring.

Question 3

What is the difference between ProGen Search and a traditional life sciences recruitment agency?

Accepted Answer

ProGen Search is an intelligence-led executive search firm, not a traditional recruitment agency. Every retained search begins with a market map covering competitor organisational charts, compensation benchmarks by geography and modality, passive talent pool identification, and realistic hiring timeline assessments. Clients receive this market intelligence as a working document alongside the candidate shortlist. The firm also publishes operator-grade market intelligence reports read by CEOs, COOs, and investors globally.

Question 4

What is radiopharma executive search?

Accepted Answer

Radiopharma executive search is a specialist recruitment service focused on placing senior leaders into radiopharmaceutical organisations. This includes developers of targeted radionuclide therapies (RLT), isotope suppliers, radiopharma CDMOs, radiopharmacy networks, and institutional investors. Key roles include VP Radiochemistry, Head of Nuclear Operations, Site Heads for shielded manufacturing facilities, CMC leads, Directors of Health Physics, and C-suite positions. ProGen Search is a specialist radiopharma executive search firm with deep expertise across this ecosystem.

Question 5

What is a CDMO executive search firm?

Accepted Answer

A CDMO executive search firm specialises in placing senior leadership into contract development and manufacturing organisations. These are companies that manufacture pharmaceutical products on behalf of drug developers. ProGen Search places Site Heads, VPs of Manufacturing, VPs of Quality, Heads of Process Development, Directors of MSAT, VPs of Business Development, and COOs into CDMOs operating across biologics, small molecule, peptide, viral vector, ADC, and radiopharmaceutical modalities.

Question 6

Does ProGen Search publish market intelligence reports?

Accepted Answer

Yes. ProGen Search publishes market intelligence reports built from live executive search mandates and operator-level conversations. Free reports are available on the Intelligence Vault covering radiopharma, CDMO, ADC, and cell & gene therapy sectors. Premium flagship reports including The State of Radiopharmaceuticals 2026 and Weaponised Capacity: The CDMO Report 2026 are available for purchase. The firm also offers bespoke commissioned intelligence briefs for boards, investors, and leadership teams.

Question 7

How does a retained executive search work at ProGen Search?

Accepted Answer

A retained executive search at ProGen Search follows six stages: (1) Discovery and mandate scoping through a confidential briefing, (2) Market mapping and intelligence including competitor org charts and compensation benchmarks, (3) Targeted candidate approach using genuine market context, (4) Assessment and shortlist of 4-6 qualified candidates against the specific mandate, (5) Client presentation with detailed candidate introduction notes written for decision-makers, and (6) Interview and offer management through to placement. Average time to placement is 8-12 weeks.

Question 8

What life sciences executive compensation data does ProGen Search provide?

Accepted Answer

ProGen Search provides executive compensation benchmarks across all seven life sciences sectors as part of retained search mandates and commissioned intelligence engagements. The firm also offers a free online Compensation Benchmark tool at progensearch.com/tools/compensation-benchmark providing indicative salary ranges for VP to C-suite roles filterable by sector, function, and geography. For bespoke, mandate-specific compensation analysis, clients can book a consultation.

Question 9

Who founded ProGen Search?

Accepted Answer

ProGen Search was founded by Byron Fitzgerald after more than 14 years in life sciences executive search. He has placed VP to C-suite leadership across Quality, MSAT, Technical Operations, CMC, Manufacturing, Regulatory, and Business Development functions for organisations ranging from pre-clinical biotechs to multinational CDMOs and radiopharma developers. His published market intelligence is read by C-suite leaders, institutional investors, and board members globally. Byron publishes regularly on LinkedIn.

Question 10

Where is ProGen Search based?

Accepted Answer

ProGen Search is based in Leeds, United Kingdom, at Ground Floor, Techno Centre, Station Road, Horsforth, Leeds, LS18 5BJ. The firm operates globally, placing senior executives across the United States, United Kingdom, Europe, and Asia-Pacific.

Articles

The Ghost Capacity Problem: Why 60% of Announced CDMO Capacity Isn't Commercially Schedulable

The Ac-225 Bottleneck: Who Actually Controls the Alpha Emitter Supply Chain?

What Happens to CROs When Every Sponsor Wants Integrated Data?

The Autologous Logistics Problem Nobody Wants to Talk About

Why Life Sciences Software Companies Keep Losing Their Best Product Leaders to Pharma

The Displacement Effect: How Section 232 Pharma Tariffs Will Deepen the Capacity Crisis for the Modalities They Exempt

The Real Story in ADCs: Market Shifts, Manufacturing Chokepoints, and the Race for Top Oncology Talent

The Alpha Architecture Question: Is Radiopharma Betting on the Wrong Supply Model?

The Analytical Hourglass: Why ADC Release Testing Is the Execution Risk Nobody Is Pricing In

The Physics of Execution: The "Early Stage" Trap in Radiopharmaceuticals

How to Hire a VP CMC for an ADC Programme

The Phantom Market: Why Radiopharma's Next Great Leap is Operational, Not Chemical

The ADC Dependency Chain: Mapping Real Talent Transfer Across the Execution Stack

How to Hire a VP Business Development for a CDMO

How to Hire a Chief Operating Officer for a Radiopharma Company

The €308M Signal: Why a Record Funding Round in Germany Signals a New Dawn for Biotech

TCR-T 2025 - From Proof to Platform

The Analytical Imperative: Why CMC Programs Are Failing in the Lab, Not the Reactor

Beyond the Ligand: Winning the Isotope Wars in Radiopharma's New Era

The Great CGT Paradox: Why Billions in New Capacity Could Soon Sit Idle

How to Hire a VP Manufacturing for Cell and Gene Therapy

How to Hire a VP MSAT for Biologics Manufacturing

The Talent Wars: Why People, Not Capital, Will Define the Future of AI Drug Discovery

The Ghost in the Machine: Why Radiopharmaceutical Talent is the New Gold Standard

The Investor's Crucible: The Questions That Are Making or Breaking Life Sciences Deals in 2025

The People Paradox: Why the Radiopharma Revolution Will Be Won by Talent, Not Just Technology

How to Hire a Head of Radiochemistry

The Evolving CDMO Landscape: Navigating a More Selective Future

How to Hire a VP Product for a Life Sciences Software Company

Execution Under Decay: Why Most Radiopharma CDMOs Will Fail - And Who Might Succeed

Reimbursement: The True Bottleneck for Radioligand Therapies in Europe?

The Bispecific Inflection Point: A Strategic Analysis of a Modality's Industrialization

The Definitive 2025 Guide to the Radiopharmaceutical Landscape: 55 Companies to Watch

ASCO 2025: The Seismic Shift for CDMOs – Adapt or Become the Bottleneck

How to Hire a VP Quality for a CDMO

The Bispecific Revolution: How Dual-Targeting Antibodies Are Reshaping Therapy and Creating a Manufacturing Bottleneck

CDMO Strategy Shift: The Modality Realignment Investors Can't Ignore

Charting Your Course: Opportunities Abound in Europe's Booming CDMO Sector (May 2025 Outlook)

TCR-T Cell Therapy: The Silent Revolution Poised for a Market Awakening

Breaking New Ground: Inside the Landmark Pfizer–3SBio Oncology Deal

AI Biotechs with Real Clinical Momentum

The Radiopharmaceutical Frontier: Navigating Manufacturing Bottlenecks with CDMOs

Leadership Volatility in CGT CDMOs: A Strategic Flashpoint

How to Hire a Site Head for a Pharmaceutical Manufacturing Facility

The Crucible of Innovation: Forging the Future of Cell & Gene Therapy Manufacturing Amidst Unprecedented Change (2025)

How to Hire a Chief Scientific Officer for a Biotech

How to Hire a Head of Process Development for Biologics

Days 2-4 at JPM - Industry Outlook

Day 1 at JPM25: High-Stakes Deals, Strategic Shifts, and Emerging Trends

How to Hire a VP Regulatory Affairs in Life Sciences

AI in Executive Search: Transforming Biotech Recruitment

Emerging Trends in CRO & CDMO Recruitment: Navigating a Competitive Landscape

Biotech Leadership: Building Resilient Teams in a Rapidly Evolving Industry

Unlocking Hidden Talent: How to Identify and Attract Passive Candidates in Biotech and CDMO Recruitment

The Science of Cultural Fit: Aligning Leadership with Organizational DNA in Biotech, CRO & CDMO

Breakthroughs and Collaborations: Recent Developments Shaping Biotech and Pharma